{"slug":"ipamorelin","seoKey":"ipamorelin","inn":"ipamorelin","displayName":"Ipamorelin","codes":["NNC 26-0161","NNC-260161"],"synonyms":["ipamorelina","ipamoreline","ipamorelin acetate","Aib-His-D-2-Nal-D-Phe-Lys-NH2","2-methylalanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-D-phenylalanyl-L-lysinamide"],"legalClass":"research_chemical","identifiers":{"cas":"170851-70-4","pubchemCid":9831659,"unii":"Y9M3S784Z6","inchikey":"NEHWBYHLYZGBNO-BVEPWEIPSA-N","wikidataQid":"Q20707829","formula":"C38H49N9O5","molecularWeight":711.9,"sequence":"Aib-His-D-2-Nal-D-Phe-Lys-NH2"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not part of any approved medicinal product. An advisory committee voted against adding it to the 503A bulks list for compounding in October 2024; it remains in category 2 of the interim compounding policies.","source":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no monograph in the European Pharmacopoeia. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=ipamorelin"},{"market":"DE","status":"not_approved","note":"No national or EU marketing authorisation; no finished medicinal product may be placed on the market. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=ipamorelin"},{"market":"UK","status":"not_approved","note":"No marketing authorisation; treated as an unlicensed medicine under the Human Medicines Regulations 2012. No entry found on 2026-09-06.","source":"https://products.mhra.gov.uk/search/?search=ipamorelin"},{"market":"AU","status":"scheduled","date":"2024-06-01","note":"Listed by name in the Poisons Standard as Schedule 4 (prescription only) and in Appendix D, clause 5, which makes possession without authority unlawful. The same entry already appeared in the June 2024 instrument. No registered finished product exists.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database. No entry found on 2026-09-06.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=ipamorelin"},{"market":"CH","status":"not_approved","note":"No marketing authorisation. A joint enforcement action by the medicines, customs and sport integrity authorities in June 2026 targeted unauthorised peptide shipments. No entry found on 2026-09-06.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"discontinued","strongestEvidence":"rct_phase2","wada":{"status":"prohibited","section":"S2","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT00672074","name":"Phase 2 study on the management of post-operative ileus","phase":"Phase 2","n":117,"status":"COMPLETED"},{"nct":"NCT01280344","name":"Phase 2 dose-finding study on recovery of gastrointestinal function after bowel resection (results unpublished)","phase":"Phase 2","n":320,"status":"COMPLETED"}],"sameAs":["https://www.wikidata.org/wiki/Q20707829","https://pubchem.ncbi.nlm.nih.gov/compound/9831659"],"lastVerified":"2026-09-06","version":"1.0","published":true,"locale":"en","title":"Ipamorelin: what the trials show, status and safety","summary":"Ipamorelin is a lab-made peptide of five building blocks that prompts the pituitary gland to release growth hormone, by docking onto the receptor for the hunger hormone ghrelin. Novo Nordisk described it in 1998, and the company Helsinn ran two mid-stage trials in patients whose bowel had gone quiet after surgery. The one published trial failed on the question it was designed to answer, and development stopped. No country has approved it, the world anti-doping list names it, and in Australia even possessing it is an offence.","updated":"2026-09-06","url":"https://mypep.app/peptides/ipamorelin"}